初级保健中阿片类药物和兴奋剂使用障碍的应急管理
应急管理作为初级保健环境中阿片类药物使用障碍和兴奋剂使用障碍的治疗方法
Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. However, there is a need to translate CM treatment to primary care settings. This study will implement and assess a CM program for patients with opioid use disorder, with or without comorbid stimulant use disorder, initiating outpatient addiction medicine services at a family medicine residency clinic. Eligible patients will earn monetary incentives for attending addiction medicine appointments and abstaining from substances during outpatient treatment. Data gathered from this pilot program will be used to improve patient outcomes, treatment, and retention for persons receiving medications for opioid use disorder (MOUDs) in a primary care setting.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 不适用
联系人和位置
学习地点
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- University of Minnesota
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- At least 18 years of age
- Diagnosis of Opioid Use Disorder and/or Stimulant Use Disorder
- Recently initiated medications for opioid use disorder (MOUDs) at Broadway Family Medicine (BFM), within 2 weeks of recruitment
- Have an active prescription for buprenorphine-naloxone (Suboxone)
Exclusion Criteria:
- Prescription for an amphetamine would exclude patients from the abstinence-based CM, but they could participate in the attendance-only CM.
- Dementia, development disabilities, or cognitive functioning that is too low to participate in study measures, as determined by chart review and consultation with overseeing physician.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
无干预:Treatment as usual (TAU)
These patients will not be assigned to the CM programs, but will be invited to complete study measures at the same time points: baseline, 3-months, 6-months, and 12-months. |
|
|
实验性的:Attendance-only CM
Patients in this arm complete an appointments with his or her primary care provider (PCP) or member of the PCP's microteam . These appointments must be initiated by the PCP/microteam in accordance with the patient's treatment plan for regular follow-up appointments. |
Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. |
|
实验性的:Attendance + abstinence CM
Patients who test stimulant-positive during the initial urine drug screen (UDS) at their intake visit will be invited to additionally enroll in the abstinence CM schedule. All of the attendance-only CM rules described previously will apply to patients in the attendance + abstinence program. |
Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Preliminary efficacy of CM on clinical outcomes: Visit Frequency
大体时间:30 days post-intervention
|
Number of completed clinical visits per patient during the CM program. |
30 days post-intervention
|
|
Preliminary efficacy of CM on clinical outcomes: Urine toxicology
大体时间:30 days post-intervention
|
Percentage of UDS results that are negative for stimulants during the CM intervention period. |
30 days post-intervention
|
|
Feasibility of CM for OUD in primary care: Recruitment
大体时间:30 days post-intervention
|
percentage of patients invited to participate enroll in the treatment intervention. |
30 days post-intervention
|
|
Feasibility of CM for OUD in primary care: Retention
大体时间:30 days post-intervention
|
Of those patients who enroll in the intervention study, the percent that complete the CM intervention period. |
30 days post-intervention
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Robert Levy, MD、University of Minnesota
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.